

# Administration

Adopted: XX-XX-XXXX

## Purpose

Administration sessions involve the supervised facilitation of a patient's medical psilocybin experience within an approved setting.

Administration sessions serve to:

- Provide a safe and supportive environment for psilocybin administration.
- Maintain patient physical and psychological safety throughout the experience.
- Support the patient during altered states of consciousness.
- Monitor physiological and psychological responses during administration.
- Ensure compliance with regulatory and facility safety requirements.
- Facilitate a therapeutic environment conducive to introspection, emotional processing, and insight.

Administration sessions occur after completion of required preparation sessions and prior to post-session integration.

## Minimum Administration Requirements

Administration sessions must meet the following minimum requirements:

- Administration must occur within an approved setting
- The Facilitator & Psychedelic Therapist must be present and available to provide support for the duration of the administration session.
- Administration must be documented in the patient's clinical record.
- Administration sessions must comply with all applicable state regulations, facility policies, and safety protocols.

## Informed Consent Confirmation

Prior to administration, facilitators must reconfirm informed consent through direct discussion with the patient. This discussion must include:

- Confirmation that the patient understands the nature of psilocybin administration
- Potential psychological and physical effects
- Possible intensity or unpredictability of the experience

- Patient rights to postpone, cancel, or delay a session at any time before administration
- Notification that administration is not covered by insurance
- Show patient the pt bill of rights
- Patient confidentiality form shall be signed before administration.
- Reaffirm boundaries with patient before administration.
- Consent confirmation must be documented prior to administration.

## Dosage and Administration

Psilocybin products must be administered according to the Psychedelic Therapists' guidance/recommendation.

Administration procedures must include:

- Verification of product identity and dosage
- Confirmation that the product was obtained through authorized channels
- Documentation of the dosage administered
- Observation of ingestion or administration by the patient
- Patients must voluntarily self-administer the product. If a patient requires assistance to self-administer, the provider and patient must discuss the need for assistance in advance and document an appropriate administration assistance plan.

Facilitators must not coerce, pressure, or physically administer psilocybin to patients.

## Facilitator Monitoring and Support

Facilitators must remain present and attentive throughout the administration session.

Responsibilities include:

- Observing patient behavior and emotional responses
- Providing reassurance and grounding support when needed
- Monitoring for signs of distress or adverse reactions
- Maintaining a calm and supportive presence
- Facilitators should generally allow patients to experience the session internally, offering non-directive facilitation only when necessary to maintain safety or stability.

## Managing Difficult Experiences

Patients may encounter emotionally challenging or intense experiences during administration.

Facilitators must be prepared to provide supportive interventions including:

- Verbal reassurance and grounding techniques
- Encouragement of breathing or relaxation strategies
- Adjustments to environmental conditions (lighting, music, position)
- Provide physical support (e.g. if patient needs help getting up when nauseous)
- Facilitators must avoid interventions that unnecessarily interrupt the patient's experience unless safety concerns arise.

## Safety and Emergency Procedures

Administration sessions must include clear protocols for managing emergencies.

Facilitators must have access to:

- Emergency medical services contact procedures
- Facility emergency protocols
- Fire and environmental safety procedures
- Communication systems for requesting assistance
- If a medical or psychological emergency occurs, facilitators must prioritize patient safety and follow established emergency procedures.

## Session Completion and Recovery

At the conclusion of the administration experience, patients must be monitored until they are stable and capable of safely leaving the facility.

Facilitators must ensure:

- Patients demonstrate adequate orientation and physical stability
- Patients have access to hydration and rest
- Patients understand post-session safety instructions

Patients must be reminded:

- Not to operate a motor vehicle for at least 24 **hours following administration**

## Transition to Integration

Usually during preparation patients should schedule and receive guidance on the integration process.

Facilitators should:

- Encourage reflection on the experience
- Provide information about scheduled integration sessions
- Offer recommendations for post-session self-care

Patients must be informed of how to contact facilitators or program staff if concerns arise following administration.

## Documentation (track & trace)

Facilitators must document administration sessions in the patient's clinical record.

Documentation must include:

- Date and duration of administration
- Identity of facilitator(s) present
- Dosage administered
- Patient observations during the session
- Any supportive interventions provided
- Confirmation of safe session completion
- Adverse Events

Documentation must also confirm that the patient was released safely.

## Timing and Clinical Oversight

Administration sessions should allow adequate time for the full psilocybin experience and recovery period.

Programs must ensure:

- A facilitator-to-patient ratio of 1:3
- Adequate staffing to maintain safety
- Compliance with regulatory and professional standards

Administration must not be rushed or conducted in a manner that compromises patient safety or therapeutic integrity.